These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33834781)

  • 1. Discovery of 5-(3-Chlorophenylamino)benzo[
    Wang Y; Lv Z; Chen F; Wang X; Gou S
    J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
    Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Anderes K; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Trent K; Rice WG; Ryckman DM
    J Med Chem; 2011 Jan; 54(2):635-54. PubMed ID: 21174434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F; Huang X; Wu M; Gou S; Hu W
    Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2.
    Vahter J; Viht K; Uri A; Enkvist E
    Bioorg Med Chem; 2017 Apr; 25(7):2277-2284. PubMed ID: 28274673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
    Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
    Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.
    Liu H; Wang X; Wang J; Wang J; Li Y; Yang L; Li G
    Int J Mol Sci; 2011; 12(10):7004-21. PubMed ID: 22072932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
    Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
    Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments.
    Wang Y; Wang X; Xu G; Gou S
    J Med Chem; 2021 Apr; 64(7):4163-4178. PubMed ID: 33784109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
    Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
    J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumoral activity of allosteric inhibitors of protein kinase CK2.
    Moucadel V; Prudent R; Sautel CF; Teillet F; Barette C; Lafanechere L; Receveur-Brechot V; Cochet C
    Oncotarget; 2011 Dec; 2(12):997-1010. PubMed ID: 22184283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
    Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
    Molecules; 2017 May; 22(5):. PubMed ID: 28534839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.
    Wang X; Pan P; Li Y; Li D; Hou T
    Mol Biosyst; 2014 May; 10(5):1196-210. PubMed ID: 24647611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
    D'Amore C; Borgo C; Sarno S; Salvi M
    Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.
    Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC
    Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.
    Bestgen B; Kufareva I; Seetoh W; Abell C; Hartmann RW; Abagyan R; Le Borgne M; Filhol O; Cochet C; Lomberget T; Engel M
    J Med Chem; 2019 Feb; 62(4):1817-1836. PubMed ID: 30689946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach.
    Borgo C; Cesaro L; Hirota T; Kuwata K; D'Amore C; Ruppert T; Blatnik R; Salvi M; Pinna LA
    Eur J Med Chem; 2021 Mar; 214():113217. PubMed ID: 33548633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.
    Bestgen B; Krimm I; Kufareva I; Kamal AAM; Seetoh WG; Abell C; Hartmann RW; Abagyan R; Cochet C; Le Borgne M; Engel M; Lomberget T
    J Med Chem; 2019 Feb; 62(4):1803-1816. PubMed ID: 30689953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin.
    Kendall JJ; Chaney KE; Patel AV; Rizvi TA; Largaespada DA; Ratner N
    Oncotarget; 2016 Aug; 7(33):53191-53203. PubMed ID: 27448963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.